SMARCB1 and rhabdoid tumor: Conversely, silencing of SMARCB1 in U2OS cells to genocopy SMARCB1‐deleted rhabdoid tumor increases the sensitivity of the cells to mithramycin almost 2‐fold from 202 to 120 nM (Figs 4F and EV2E).